Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

NCT ID: NCT04525209

Last Updated: 2020-08-25

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-10-01
• Study Completion Date: 2022-12-31

Brief Summary

A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will be carried out. In this study, clinical specimens of resected PDAC collected by our research group from 2017 to 2019 will be selected as research objects.Tumor tissues and their adjacent non-tumor tissues from more than 200 PDAC patients are expected to be used for genome, transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated proteome.Combined with the data results of multiomics, bioinformatics analysis and network database information, we will clarify the relationship between multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer proteome. A molecular landscape of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides new therapeutic targets to improve the prognosis of this deadly disease.

Conditions

Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

No intervention

No intervention

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology;

2. The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage;

2. There are few tissue specimens, only enough for clinical diagnosis;

3. Patients are unwilling to conduct follow-up study;

4. For the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ruijin Hospital

OTHER

Sponsor Role: lead

Responsible Party

HAOCHEN

Chen Hao

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Hao Chen, MD

Role: PRINCIPAL_INVESTIGATOR

Ruijin Hospital

Locations

RUIJIN Hospital

Shanghai, Shanghai Municipality, China

Countries

China

Central Contacts

Hao Chen, MD

Role: CONTACT

haochendr@126.com

13003135899

Lingxi Jiang, Ph.D

Role: CONTACT

jlx12120@rjh.com.cn

13818826142

Facility Contacts

Jian Li, Ph.D

Role: primary

References

Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja E, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell. 2019 Oct 3;179(2):561-577.e22. doi: 10.1016/j.cell.2019.08.052.

Reference Type: BACKGROUND

PMID: 31585088 (View on PubMed)

Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.

Reference Type: RESULT

PMID: 28810144 (View on PubMed)

Other Identifiers

2020-08-20

Identifier Type: -

Identifier Source: org_study_id